Efficacy and safety of pegylated interferon-α2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 22, Issue 4, 2006, Pages 315-320

  Santin, Miguel ^a   Shaw, Evelyn ^a   Garcia, M Jose ^b   Delejido, Antonio ^c   Rodriguez De Castro, Eduardo ^d   Rota, Rosa ^e   Altés, Jordi ^f   Baguena, Francisco ^g   Valero, Silvia ^h   Sala, Montserrat ⁱ   Casanova, Aurora ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Hospital de Can Misses   (Spain)

^c Hospital de St Pau i Sta Tecla   (Spain)

^d Hospital Verge del Toro   (Spain)

^e HOSPITAL DE VILADECANS   (Spain)

^f Internal Medicine Service   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h Hospital Sant Jaume de Calella   (Spain)

ⁱ Hospital Pare Tauli   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; PEGINTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; LOGISTIC MODELS; MALE; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33646163653     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.315     Document Type: Article

References (18)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998;338:853-860.
2. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Muñoz F, and Gonzalez-Lahoz J: Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4.
3. Sulkowski M and Thomas D: Hepatitis C in the HIV-infected person. Ann Intern Med 2003;138:197-207.
4. Soriano V, Puoti M, Sulkowski Mark, et al.: Care of patients with hepatitis C and HIV co-infection. AIDS 2004;18:1-12.
5. Strader DB, Wright T, Thomas DL, and Seeff LB: Diagnosis, management and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
6. Sauleda S, Juárez A, Esteban JI, et al.: Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders. Hepatology 2001;34:1035-1040.
7. Pérez-Olmeda M, Núñez M, Romero M, et al.: Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003;17:1023-1028.
8. Mauss S, Valenti W, DePamphilis, et al.: Risk factors for hepatic descompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-F25.
9. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA 2004;292:2839-2848.
10. Manns MP, McHutchinson JG, Gordon SC, Rutgi VK, Shiffman M, Reindollar R, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-965.
11. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
12. Conseil Assessor for Treatment of Viral Hepatitis. Department of Health. Generalitat de Catalunya: http://www.gencat.net/sanitat/portal/cat/catfhv.htm.
13. Thiers V, Jaffredo F, Tuveri R, Chodan N, and Brechet Ch: Development of a simple restriction fragment length polymosphism (RFLP) based assay for genotyping and comparative analysis with genotyping and serotyping tests. J Virolog Methods 1997;65:9-17.
14. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
15. Laguno M, Murillas J, Blanco JL, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004;18:F27-F36.
16. Lafeuillade A, Hittinger G, and Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV / HCV coinfection. Lancet 2001;357:280-281.
17. Soriano V, Perez-Olmeda M, Rios P, Nuñez M, Garcia-Samaniego J, and Gonzalez-Lahoz J: Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses 2004;20:351-353.
18. Ballesteros AL, Franco S, Fuster D, et al.: Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: Indications for the investigation of new treatment approaches. AIDS 2004;18:59-66.